Comparison of quality of life between 2-year and 3-or-more-year administration of leuprorelin acetate every-3-months depot in combination with tamoxifen as adjuvant endocrine treatment in premenopausal patients with endocrine-responsive breast cancer: a randomized controlled trial

What Was Tested

Researchers studied Leuprolide in this randomized controlled trial publication.

The researchers hereby present patient-reported quality of life (QOL) data obtained from this trial.

Who Took Part

By PubMed's age tags, the people studied were adults and middle-aged adults, women only.

How the Study Was Run

The researchers set it up as a randomized and open-label study.

Random assignment meant chance, not the researchers, decided who got Leuprolide and who got the comparison, which limits bias.

Everyone knew when Leuprolide was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

Three self-administered QOL questionnaires (QOL-ACD, QOL-ACD-B, FACT-ES subscale) were used, and the difference in QOL score changes between the two groups was analyzed using a mixed-effects model for repeated measures.

What Was Measured

Topics PubMed links to this paper include Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Chemotherapy, Adjuvant, Leuprolide, Premenopause, Quality of Life and Tamoxifen.

Author keywords: Adjuvant endocrine therapy, Leuprorelin acetate, Luteinizing hormone-releasing hormone agonist and Premenopausal endocrine-responsive breast cancer.

What This Means in Plain Language

The paper is a randomized and open-label study of Leuprolide.

The abstract goes on to report its results in about 7 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2018 (Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer), a journal based in Germany.

More context: the Leuprolide compound page, all human trials.